Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Cardiotoxicity 7Lymphoma, Non-Hodgkin 5Breast Neoplasms 5Neoplasms 4Lymphoma 4Prostatic Neoplasms 3Myelodysplastic Syndromes 3Lung Neoplasms 3Leukemia 3Hematologic Neoplasms 3Heart Failure 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Dyslipidemias 2Colonic Neoplasms 2Cardiovascular Diseases 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Ventricular Dysfunction, Left 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1

Interventions

Etoposide 9Rituximab 8Cyclophosphamide 7Vincristine 6Prednisone 6Doxorubicin 5Filgrastim 4Cytarabine 3Radiotherapy 2Procarbazine 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Lomustine 2Carmustine 2prednylidene 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1ibrutinib 1ibritumomab tiuxetan 1etoposide phosphate 1efavirenz 1deltacortene 1VAP-cyclo protocol 1Ultrasonography 1Radioimmunotherapy 1Ondansetron 1O(6)-benzylguanine 1Mitoguazone 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, AIDS-Related × Electrocardiography × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡